BMRN250117C130000
- 0.30
- 0.000.00%
Biomarin Pharmaceutical Newsroom
Express News | Biomarin Pharmaceutical Inc : BofA Global Research Cuts Price Objective to $100 From $101
BioMarin to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, at 9:00 Am PT / 12:00 Pm ET, in San Francisco, CA
3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)
Top U.S. Health Care Mid-cap Stocks and Their Quant Ratings
Why Did Pfizer's Exit From the Gene Therapy Program Hit Sangamo Hard?
Why BioMarin Pharmaceutical (BMRN) Is a Top Growth Stock for the Long-Term
Is the Options Market Predicting a Spike in BioMarin Pharmaceutical (BMRN) Stock?
Does BioMarin Pharmaceutical (NASDAQ:BMRN) Have A Healthy Balance Sheet?
Worst Performing Stocks for Tax Loss Selling – Wolfe
Express News | Cantor Fitzgerald Reiterates Overweight on Biomarin Pharmaceutical, Maintains $90 Price Target
Are BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?
11 Compounder Opportunities According to Goldman: AMD, BDX, INFA
BofA Securities Initiates Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Announces Target Price $101
J.P. Morgan Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating
Biomarin Pharmaceutical To Present At Evercore ISI HealthCONx Conference; Webcast At 10:00 AM ET
RBC Capital Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN)
Despite Delivering Investors Losses of 26% Over the Past 1 Year, BioMarin Pharmaceutical (NASDAQ:BMRN) Has Been Growing Its Earnings
Express News | Biomarin Pharmaceutical Inc : RBC Cuts Target Price to $70 From $80
Here's Why BioMarin Pharmaceutical (BMRN) Is a Strong Value Stock
Jefferies Maintains Biomarin Pharmaceutical(BMRN.US) With Buy Rating, Maintains Target Price $122